JPM26: J&J reveals oncology strategy [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Duato identified six major growth drivers, three in pharma (oncology, immunology, and neuroscience) and three in medtech (surgery, cardiovascular, and vision). These drivers position J&J to reach 5-7% annual growth and even exceeding that by the end of the decade, with potential to reach double digit growth in the 2030s. Oncology is set to play a major role in J&J's optimistic revenue outlook, generating $50bn. The oncology portfolio will be driven by J&J's continuing dominance in multiple myeloma (MM), which J&J hopes will reach $25bn in sales in 2030. J&J's largest franchise, Darzalex/Faspro (daratumumab), will make up over half of this, as it is central to many current, as well as pipeline MM regimens. J&J also expect a significant increase in sales for their cell therapy, Carvykti (ciltacabtagene autoleucel), despite general headwinds in the cell therapy market. Carvykti sales are not restricted from a supply perspective, and it is also expected to gain a significant portion o
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]Yahoo! Finance
- Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]Yahoo! Finance
- Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]CNBC
- [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]Latest
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- BMY's page on the SEC website